男友太凶猛1v1高h,大地资源在线资源免费观看 ,人妻少妇精品视频二区,极度sm残忍bdsm变态

Global EditionASIA 中文雙語Fran?ais
China
Home / China / Health

Chinese scholars publish biologics guideline in international journal

By Chen Meiling | chinadaily.com.cn | Updated: 2025-05-07 20:26
Share
Share - WeChat

A Chinese guideline on the use of biologic agents in treating chronic rhinosinusitis with nasal polyps was recently published in the 2025 China Issue of Allergy, one of the most prestigious journals in the global fields of allergology and clinical immunology.

It focuses on China-specific clinical data, systematically standardizing key aspects of biologic treatment, such as patient selection, therapeutic protocols and efficacy evaluation, providing authoritative guidance for clinical practice.

"Emerging biologics that selectively target key cytokines present a promising therapeutic alternative for patients suffering from severe, uncontrollable chronic rhinosinusitis with nasal polyps," according to the guideline.

It's the first time that Chinese scholars have published a guideline-type document in a top-tier international journal in this field, offering valuable Chinese experience for global biologic applications, said Zhang Luo, president of Beijing Tongren Hospital and guest editor of the issue, at a news conference in Beijing on Wednesday.

"In the last two decades, the problems of allergic diseases have been increasing dramatically in the world. Now we are facing 2 billion patients with allergic diseases, so this is a serious threat to humankind in the future," he said.

"In the past, we primarily relied on nasal corticosteroid sprays and oral antihistamines, both of which are chemical-based medications. These treatments have been widely used and can effectively control symptoms. However, since they require frequent administration (often daily), patients may find them inconvenient. Now, with these new biologics, just about three injections over an allergy season can effectively manage symptoms. In terms of both efficacy and duration of effect, they represent an improvement over traditional treatments," Zhang said.

He said these medicines are now available in major hospitals, such as in his hospital. However, since biologics are relatively new, their cost remains high — for example, a single injection may cost around 1,000 to 2,000 yuan ($138-276). "But as their use becomes more widespread, prices are expected to gradually decrease, making them more accessible to a larger number of patients," he added.

The 2025 China Issue of Allergy includes 32 articles focusing on the latest research progress of Chinese scholars in areas such as the link between environmental pollution and asthma pathogenesis, gut microbiota dysbiosis and allergies, as well as the mechanisms underlying drug hypersensitivity.

Cezmi Akdis, editor-in-chief of the journal Allergy, the official journal of the European Academy of Allergy and Clinical Immunology, praised China's contribution to the study of allergy, which has "immensely increased" in the last two decades.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
 
主站蜘蛛池模板: 高碑店市| 广昌县| 大英县| 乌兰浩特市| 侯马市| 嘉善县| 锡林浩特市| 海门市| 上林县| 宁蒗| 拜泉县| 灵宝市| 邮箱| 平原县| 托克逊县| 大名县| 岫岩| 阳城县| 涿州市| 建湖县| 长丰县| 原平市| 镇原县| 吴川市| 敦化市| 靖安县| 扎兰屯市| 奉节县| 井冈山市| 哈巴河县| 宾川县| 东平县| 彭水| 济阳县| 武宣县| 西城区| 四平市| 简阳市| 邯郸县| 天台县| 建始县|